160 related articles for article (PubMed ID: 38524940)
21. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
Yang W; Ma J; Hong T; Liu M; Miao H; Peng Y; Wang C; Xu X; Yang T; Nielsen AM; Pan L; Liu W; Zhao W
Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
[TBL] [Abstract][Full Text] [Related]
22. Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials.
Janez A; Őrsy P; Stachlewska K; Salvesen-Sykes K; Billings LK; Philis-Tsimikas A
Diabetes Obes Metab; 2020 Apr; 22(4):658-668. PubMed ID: 31858673
[TBL] [Abstract][Full Text] [Related]
23. Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.
Rodbard HW; Buse JB; Woo V; Vilsbøll T; Langbakke IH; Kvist K; Gough SC
Diabetes Obes Metab; 2016 Jan; 18(1):40-8. PubMed ID: 26343931
[TBL] [Abstract][Full Text] [Related]
24. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
Rodbard HW; Cariou B; Pieber TR; Endahl LA; Zacho J; Cooper JG
Diabetes Obes Metab; 2016 Mar; 18(3):274-80. PubMed ID: 26592732
[TBL] [Abstract][Full Text] [Related]
25. The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting.
Drummond R; Malkin S; Du Preez M; Lee XY; Hunt B
Diabetes Obes Metab; 2018 Oct; 20(10):2371-2378. PubMed ID: 29797389
[TBL] [Abstract][Full Text] [Related]
26. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.
Aroda VR; González-Galvez G; Grøn R; Halladin N; Haluzík M; Jermendy G; Kok A; Őrsy P; Sabbah M; Sesti G; Silver R
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):596-605. PubMed ID: 31189519
[TBL] [Abstract][Full Text] [Related]
27. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
Evans M; Billings LK; Håkan-Bloch J; Slothuus U; Abrahamsen TJ; Andersen A; Jansen JP
J Med Econ; 2018 Apr; 21(4):340-347. PubMed ID: 29164973
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with One Year of IDegAsp Therapy in Poorly Controlled and Non-compliant Patients.
Kırkgöz T; Eltan M; Kaygusuz SB; Yavaş Abalı Z; Helvacıoğlu D; Seven Menevşe T; Gürpınar Tosun B; Güran T; Bereket A; Turan S
J Clin Res Pediatr Endocrinol; 2022 Mar; 14(1):10-16. PubMed ID: 34355879
[TBL] [Abstract][Full Text] [Related]
29. Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes.
Bebakar WM; Chaykin L; Hersløv ML; Rasmussen S
Diabetes Ther; 2017 Feb; 8(1):197-205. PubMed ID: 27853981
[TBL] [Abstract][Full Text] [Related]
30. Intensification of Insulin Treatment With Insulin Degludec/Aspart in Type 2 Diabetic Patients: A 2-Year Real-World Experience.
Oner H; Gunhan HG; Gogas Yavuz D
Front Clin Diabetes Healthc; 2022; 3():783277. PubMed ID: 36992737
[TBL] [Abstract][Full Text] [Related]
31. Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.
Østergaard L; Frandsen CS; Dejgaard TF; Madsbad S
Expert Rev Clin Pharmacol; 2017 Jun; 10(6):621-632. PubMed ID: 28349716
[TBL] [Abstract][Full Text] [Related]
32. Switching from Multiple Insulin Injections to a Fixed Combination of Degludec and Liraglutide in Patients with Type 2 Diabetes Mellitus: Results from the Simplify Study After 6 Months.
Martinka E; Dravecká I; Tkáč I
Diabetes Ther; 2023 Sep; 14(9):1503-1515. PubMed ID: 37402960
[TBL] [Abstract][Full Text] [Related]
33. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.
Philis-Tsimikas A; Billings LK; Busch R; Portillo CM; Sahay R; Halladin N; Eggert S; Begtrup K; Harris S
Diabetes Obes Metab; 2019 Jun; 21(6):1399-1408. PubMed ID: 30761720
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
Billings LK; Doshi A; Gouet D; Oviedo A; Rodbard HW; Tentolouris N; Grøn R; Halladin N; Jodar E
Diabetes Care; 2018 May; 41(5):1009-1016. PubMed ID: 29483185
[TBL] [Abstract][Full Text] [Related]
35. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.
Haluzík M; Fulcher G; Pieber TR; Bardtrum L; Tutkunkardas D; Rodbard HW
Diabetes Obes Metab; 2018 Jul; 20(7):1585-1592. PubMed ID: 29451706
[TBL] [Abstract][Full Text] [Related]
36. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.
Persano M; Nollino L; Sambataro M; Rigato M; Negro I; Marchetto S; Paccagnella A
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):923-931. PubMed ID: 33577047
[TBL] [Abstract][Full Text] [Related]
37. Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin.
Jammah AA
Prim Care Diabetes; 2021 Feb; 15(1):132-137. PubMed ID: 32839127
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
[TBL] [Abstract][Full Text] [Related]
39. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
[TBL] [Abstract][Full Text] [Related]
40. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
Buse JB; Vilsbøll T; Thurman J; Blevins TC; Langbakke IH; Bøttcher SG; Rodbard HW;
Diabetes Care; 2014 Nov; 37(11):2926-33. PubMed ID: 25114296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
